Activity_NN
of_IN
the_DT
kappa_NN
B_NN
enhancer_NN
of_IN
the_DT
interleukin-2_NN
receptor_NN
alpha_NN
chain_NN
in_IN
somatic_JJ
cell_NN
hybrids_NNS
is_VBZ
accompanied_VBN
by_IN
the_DT
nuclear_JJ
localization_NN
of_IN
NF-kappa_NN
B_NN
._.

The_DT
two_CD
nuclear_JJ
proteins_NNS
NF-kappa_NN
B_NN
-LRB-_-LRB-
consisting_VBG
of_IN
subunits_NNS
p50_NN
and_CC
p65_NN
-RRB-_-RRB-
and_CC
the_DT
DNA-binding_JJ
subunit_NN
of_IN
NF-kappa_NN
B_NN
-LRB-_-LRB-
p50_NN
-RRB-_-RRB-
by_IN
itself_PRP
,_,
also_RB
called_VBN
KBF1_NN
,_,
are_VBP
constitutively_RB
expressed_VBN
and_CC
localized_JJ
in_IN
the_DT
nucleus_NN
of_IN
the_DT
human_JJ
T-cell_NN
line_NN
IARC_NN
301.5_CD
._.

In_IN
order_NN
to_TO
define_VBP
the_DT
roles_NNS
of_IN
these_DT
two_CD
factors_NNS
,_,
which_WDT
bind_VBP
to_TO
the_DT
same_JJ
kappa_NN
B_NN
enhancers_NNS
,_,
in_IN
transcription_NN
activation_NN
we_PRP
have_VBP
prepared_VBN
somatic_JJ
cell_NN
hybrids_NNS
between_IN
IARC_NN
301.5_CD
and_CC
a_DT
murine_JJ
myeloma_NN
._.

Most_JJS
hybrids_NNS
express_VBP
both_CC
KBF1_NN
and_CC
NF-kappa_NN
B_NN
in_IN
their_PRP$
nuclei_NNS
,_,
but_CC
one_CD
hybrid_NN
expresses_VBZ
only_RB
KBF1_NN
._.

The_DT
kappa_NN
B_NN
enhancer_NN
of_IN
the_DT
gene_NN
encoding_VBG
the_DT
interleukin-2_NN
-LRB-_-LRB-
IL-2_NN
-RRB-_-RRB-
receptor_NN
alpha_NN
chain_NN
-LRB-_-LRB-
IL-2R_NN
alpha_NN
-RRB-_-RRB-
is_VBZ
functional_JJ
only_RB
in_IN
the_DT
hybrids_NNS
expressing_VBG
nuclear_JJ
NF-kappa_NN
B_NN
._.

These_DT
findings_NNS
show_VBP
that_IN
nuclear_JJ
NF-kappa_NN
B_NN
is_VBZ
necessary_JJ
to_TO
activate_VB
the_DT
kappa_NN
B_NN
enhancer_NN
,_,
while_IN
KBF1_NN
by_IN
itself_PRP
is_VBZ
not_RB
sufficient_JJ
._.

We_PRP
propose_VBP
that_IN
KBF1_NN
is_VBZ
a_DT
competitive_JJ
inhibitor_NN
of_IN
NF-kappa_NN
B_NN
and_CC
discuss_VBP
how_WRB
these_DT
factors_NNS
may_MD
be_VB
involved_VBN
in_IN
the_DT
transient_JJ
expression_NN
of_IN
IL-2_NN
and_CC
IL-2R_NN
alpha_NN
genes_NNS
during_IN
the_DT
immune_JJ
response_NN
._.

